Navigation Links
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Date:5/30/2008

5, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the `Business Review' in the company's Annual Report on Form 20-F for 2007.

References:

(1) Kruit W, Suciu S, Dreno B, et al `Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC Melanoma Group J Clin Oncol 26: 2008 (May 20 suppl; abstr 9065).

(2) Louahed J, Gruselle O, Gaulis S et al `Expression of defined genes by identified by pre-treatment tumor profiling: association with clinical responses to the GSK MAGE-A3 immunotherapuetic in metastatic melanoma patients, J Clin Oncol 26: 2008 (May 20 suppl; abstr 9045).

(3) Vansteenkiste J, Zielinski M, Linder A et al `Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC)' J Clin Oncol 26: 2008 (May 20 suppl; abstr 7501).

(4) Vansteenkiste J, Zielinski M, Linder A et al `Final results of a multi-center, double-blind, randomized, placebocontrolled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II Non-Small Cell Lung Cancer (NSCLC)' Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 7554.

(5) http://www.who.int/uv/faq/skincancer/en/index1.html (Date of access: May 6, 2008).

(6)


SOURCE GlaxoSmithKline (GSK)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Presentation of Data on Progens Cancer Epigenetic Targets Platform
2. Genmab Announces Updates on Phase III Cancer Studies
3. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
4. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
5. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
6. Prostate Cancer Treatment Offers Results Without Side Effects
7. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
8. First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab in Early Breast Cancer
9. Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy
10. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
11. Ovarian Cancer Vaccine Clinical Trial Begins at Cancer Treatment Centers of America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... DALLAS , March 31, 2015 ... H1 2015" therapeutic market research report of 68 ... its online business intelligence library. The ... information on the therapeutic development for Pemphigus ... therapeutics assessment by drug target, mechanism of action ...
(Date:3/31/2015)... N.C. , March 31, 2015  Dr. Renu ... be attending the World Orphan Drug Congress in April to ... regulatory approval process and orphan drugs below: ... has recommended to the Ministry of Health that if a ... marketing authorization can be obtained in India ...
(Date:3/31/2015)... March 31, 2015   Halyard Health (NYSE: ... it was awarded a new purchasing agreement with ... Effective March 1, 2015, Halyard,s standard and ASTM-rated ... lining, will be available to HealthTrust members made up ... ambulatory surgery centers, physician practices and alternate care facilities. ...
Breaking Medicine Technology:Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4Max Neeman to Discuss India's Orphan Drug Regulations at WOD 2015 2Halyard Health Signs First GPO Contracts As Independent Company 2Halyard Health Signs First GPO Contracts As Independent Company 3
... - New Platform May Provide Solutions ... Alloksys Life Sciences BV (Bunnik, The Netherlands), ... announce the start of Theraptech, a 2.4 million Euro ... Program.,The major objective of the Theraptech project is to ...
... CHICAGO, March 2 The Society of Gynecologic Oncologists ... (ACOG) have jointly developed a breast disease fellowship training ... of $75,000 from ACOG, the program provides support for ... in the care and treatment of breast cancer and ...
Cached Medicine Technology:Drug Development Program Started Based on CAP(R) Human Cell Line 2Drug Development Program Started Based on CAP(R) Human Cell Line 3SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 2SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 3
(Date:3/31/2015)... 2015 Dr. St. Ledger recently returned from ... Dental Education. Here, he participated in the Worn Dentition ... a greater predictability in cases of severely worn teeth, as ... wear, and the correlation to GERD and Sleep Apnea. ... Spear Education. After the workshop he attended, he mentored ...
(Date:3/31/2015)... La Mirada, CA (PRWEB) March 31, 2015 ... now treating hip injuries at all of their clinics. ... injuries or disorders. , For athletes with hip ... specialists ready to assess and treat the symptoms and ... athletes to provide minimally-invasive care and prevent future damage, ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Beckman Coulter is ... new USP 787: “Subvisible Particulate Matter in Therapeutic Protein Injections”,” ... the new demands in counting particles in liquids, with a ... The webinar is free to attend and will be broadcast ... recently posted a new test for protein-based materials, known as ...
(Date:3/31/2015)... 31, 2015 Indosoft, Inc., developers of ... the availability of SIP over TCP configuration for all SIP ... offering a full contact center ACD (Automatic Call ... Adding SIP over TCP support to all SIP devices gives ... The history of Voice over IP (VoIP) has primarily involved ...
(Date:3/31/2015)... 2015 Greenfield Senior continues to ... LLC ("Care") a seniors housing-focused real estate investment ... announces today, their acquisition of six senior housing ... million. Concurrent with the acquisition, Care will master ... Living ("Greenfield"). Pursuant to the lease, Care will ...
Breaking Medicine News(10 mins):Health News:The dentists at Upper Montclair Dental Associates are happy to announce exciting new happenings at their practice. 2Health News:Healthpointe Now Treating Hip Dislocations, Hip Fractures, Hip Bursitis, and Hip Strains at Locations in Southern California 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 2Health News:Beckman Coulter Webinar Series Presents Insight into New Demands in Counting Particles in Liquids 3Health News:Indosoft extends SIP over TCP support to User Extensions in its Q-Suite 5.9 Call Center Software 2Health News:Greenfield Senior Living Inc. Enters Lease Transaction with Care Investment Trust LLC 2Health News:Greenfield Senior Living Inc. Enters Lease Transaction with Care Investment Trust LLC 3
... News) -- People who have dealings with the criminal justice system ... been found guilty or spent time in prison, a new study ... Denmark who died of suicide between 1981 and 2006 and compared ... population. The study found that 34.8 percent of men who ...
... - So-called barrier sites -- the skin, gut, lung ... viruses, bacteria, and parasites. Understanding how the immune system ... such inflammatory diseases as asthma, psoriasis, IBD, and food ... David Artis, PhD, professor of Microbiology and ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... and introduced to solid foods before they were 4 months ... 3, researchers report. The timing of solid foods didn,t ... breast-fed. But among children who were never breast-fed -- or ...
... Despite decades of research and billions of dollars, cancer ... evade both the body,s defenses and medical intervention. Now ... explanation. "Cancer is not a random bunch of ... response to stress, honed by a long period of ...
... Church of Sweden decided to introduce a special blessing ... Church making a distinction between genuine homosexuality and promiscuous ... by a new thesis in religious studies at the ... values between opponents and supporters of the decision. ...
... used by statisticians to analyze data is helping Houston ... and Parkinson,s diseases and stroke. Researchers at Rice ... at Houston (UTHealth) reported today in the journal ... energy transfer (FRET) techniques combined with wavelet transforms have ...
Cached Medicine News:Health News:Brushes With the Law Raise Suicide Risk, Study Shows 2Health News:Giving Baby Solid Foods Too Early Linked to Obesity Later 2Health News:Giving Baby Solid Foods Too Early Linked to Obesity Later 3Health News:Conceptualizing cancer cells as ancient 'toolkit' 2Health News:Supporters and opponents of a special blessing for homosexuals share many values 2Health News:Researchers get a grip on nervous system's receptors 2Health News:Researchers get a grip on nervous system's receptors 3
... Cardiology Hemo is a comprehensive hemodynamic ... the cath lab. Patient demographics, ... images and procedural information all flow ... record, eliminating repetitive data entry. ...
The flexible EXXCEL ePTFE Vascular Access Graft material is designed to offer textile-like handling characteristics-cuts neatly for a clean edge, retains fully open lumen shape, and sutures smoothly....
Data Trol™ Normal Control Serum provides the laboratory with vital information on the performance of clinical chemistry assays in the Normal range....
... Data Trol™ Abnormal Control Serum is intended for ... clinical chemistry assays. It is for in vitro ... 5ml lyophilized format, the control offers up to ... reconstituted. The control is to be used in ...
Medicine Products: